Want to see CNTX full AI Analyst Report?
CNTX Stock Chart & Stats
$0.44
<$0.01(1.34%)
At close: 4:00 PM EDT
$0.44
<$0.01(1.34%)
Day’s Range― - ―
52-Week Range$0.22 - $3.62
Previous Close$0.61
Volume1.73M
Average Volume (3M)1.05M
Market Cap
$21.90M
Enterprise Value$9.98M
Total Cash (Recent Filing)$42.99M
Total Debt (Recent Filing)$244.99K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 11, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding91,879,170
10 Day Avg. Volume1,015,346
30 Day Avg. Volume1,046,251
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.45K
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$3.20Price Target Upside627.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Context greater financial flexibility than a heavily indebted development-stage biotech. With minimal debt obligations, the company faces less interest burden and refinancing pressure, preserving more capacity to direct funding toward clinical development and other strategic priorities.
Pipeline ProgressProgress across CTIM-76 and CT-202 provides identifiable development milestones that could advance the company toward clinical validation. A defined pipeline and upcoming milestones support a pathway to potential value creation, while broad solid-tumor applications provide multiple opportunities for program expansion.
Differentiated TCE StrategyA focus on selective, conditionally active T cell engagers may help Context distinguish its programs in a competitive immuno-oncology field. The stated aim to improve efficacy and limit cytokine release syndrome could support broader use and combination strategies if clinical results validate the design.
Bears Say
Pre-Revenue ModelThe absence of commercial revenue means Context remains dependent on external financing or potential strategic transactions to fund operations. Until a candidate is approved and commercialized, the company has no recurring product-sales base to offset research spending or support self-funded growth.
Widening Losses And BurnIncreasing losses and worsening cash burn raise the amount of capital required to sustain the pipeline over the next several quarters. Continued negative operating economics can reduce financial flexibility, increase dependence on new funding, and make development progress more sensitive to financing availability.
Nasdaq Listing ComplianceThe minimum-bid-price deficiency creates an ongoing listing-compliance risk that may require corporate action during the stated compliance period. Failure to regain compliance could ultimately threaten Nasdaq listing status, adding governance and financing complexity while the company funds its clinical programs.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.22 and its highest was $3.62 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $21.90M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.092 by -$0.058.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.092. Following the earnings report the stock price went down -27.273%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$3.20
▲(627.27% Upside)
Technical Analysis
Ownership Overview
1.35%
Insiders
5.78% Mutual Funds
0.23% Other Institutional Investors
84.37% Public Companies and
Individual Investors